UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
olaparib (208) 208
life sciences & biomedicine (167) 167
science & technology (167) 167
oncology (119) 119
ovarian cancer (115) 115
humans (108) 108
female (79) 79
mutation (62) 62
breast cancer (57) 57
cancer (53) 53
chemotherapy (46) 46
phthalazines - therapeutic use (46) 46
piperazines - therapeutic use (46) 46
ovarian neoplasms - drug therapy (44) 44
poly polymerase (44) 44
parp inhibitor (43) 43
pharmacology & pharmacy (40) 40
dna repair (38) 38
cancer therapies (37) 37
tumors (37) 37
antineoplastic agents - therapeutic use (36) 36
deoxyribonucleic acid--dna (36) 36
parp inhibitors (35) 35
clinical trials (32) 32
dna damage (32) 32
phthalazines - pharmacology (30) 30
piperazines - pharmacology (30) 30
poly polymerase inhibitors - therapeutic use (30) 30
animals (28) 28
ovarian neoplasms - genetics (28) 28
ribose (28) 28
brca (25) 25
niraparib (25) 25
phthalazines - administration & dosage (25) 25
medicine & public health (24) 24
middle aged (24) 24
piperazines - administration & dosage (24) 24
poly polymerase inhibitors - pharmacology (24) 24
care and treatment (23) 23
monosaccharides (23) 23
research (23) 23
sugars (23) 23
homologous recombination (22) 22
rucaparib (22) 22
cell cycle (21) 21
cell line, tumor (21) 21
parp (21) 21
poly polymerase inhibitors (21) 21
antineoplastic agents - pharmacology (20) 20
patients (20) 20
aged (19) 19
phthalazines - adverse effects (19) 19
piperazines - adverse effects (19) 19
adult (18) 18
drug therapy (18) 18
neoplasms - drug therapy (18) 18
neoplasms. tumors. oncology. including cancer and carcinogens (18) 18
brca1 protein (17) 17
brca1 protein - genetics (17) 17
male (17) 17
review (17) 17
veliparib (17) 17
apoptosis (16) 16
bevacizumab (16) 16
brca mutation (16) 16
kinases (16) 16
proteins (16) 16
analysis (15) 15
brca1 (15) 15
brca2 protein - genetics (15) 15
breast neoplasms - drug therapy (15) 15
genes, brca1 (15) 15
phthalazines - pharmacokinetics (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
metastasis (14) 14
piperazines - pharmacokinetics (14) 14
antineoplastic agents - adverse effects (13) 13
cytotoxicity (13) 13
genes (13) 13
health aspects (13) 13
inhibitors (13) 13
medical research (13) 13
ovarian neoplasms - pathology (13) 13
poly polymerase inhibitors - administration & dosage (13) 13
treatment outcome (13) 13
cell biology (12) 12
drug dosages (12) 12
endocrine system diseases (12) 12
molecular targeted therapy (12) 12
obstetrics & gynecology (12) 12
pharmacology/toxicology (12) 12
poly polymerases - metabolism (12) 12
brca2 (11) 11
cell death (11) 11
pancreatic cancer (11) 11
poly polymerase inhibitors - adverse effects (11) 11
safety (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
fda approval (10) 10
gene expression (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 12/2016, Volume 375, Issue 22, pp. 2154 - 2164
Journal Article
Journal Article
Cancer management and research, ISSN 1179-1322, 2019, Volume 11, pp. 3061 - 3078
.... In this article, we assessed the efficacy and safety of olaparib maintenance therapy on platinum-sensitive ovarian cancer patients with BRCA mutations through a meta-analysis of available randomized controlled trials (RCTs... 
Adverse event | Efficacy | Olaparib | Meta-analysis | Ovarian cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Clinical trials | Mutation | Quality of life | meta-analysis | adverse event | ovarian cancer | efficacy | olaparib
Journal Article
Journal Article
Journal Article
OncoTargets and therapy, ISSN 1178-6930, 12/2019, Volume 12, pp. 11497 - 11506
.... Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer... 
Oncology | Life Sciences & Biomedicine | Biotechnology & Applied Microbiology | Science & Technology | parp inhibitor | ovarian cancer | maintenance | olaparib
Journal Article